| Assay Name | Tissue | Organism | Target Gene ID | Target HGNC Symbol | Response | AC50 Value |
|---|
| CCTE_GLTED_hTTR_0.125uM | | Human | 7276 | TTR | Loss | 2.22 μM |
| ATG_AP_1_CIS | Liver | Human | 2353|3725 | FOS|JUN | Inhibitory | 5.43 μM |
| ATG_DR4_LXR_CIS | Liver | Human | 7376|10062 | NR1H2|NR1H3 | Activatory | 8.79 μM |
| ATG_ERE_CIS | Liver | Human | 2099 | ESR1 | Inhibitory | 0.09 μM |
| ATG_IR1_CIS | Liver | Human | 9971 | NR1H4 | Activatory | 9.95 μM |
| ATG_ISRE_CIS | Liver | Human | 3659 | IRF1 | Activatory | 11.1 μM |
| ATG_NRF2_ARE_CIS | Liver | Human | 4780 | NFE2L2 | Inhibitory | 11.1 μM |
| ATG_PXRE_CIS | Liver | Human | 8856 | NR1I2 | Activatory | 2.73 μM |
| ATG_TCF_b_cat_CIS | Liver | Human | 6932|6934|51176|83439 | TCF7|TCF7L2|LEF1|TCF7L1 | Activatory | 11.1 μM |
| ATG_VDRE_CIS | Liver | Human | 7421 | VDR | Inhibitory | 14.92 μM |
| ATG_ERa_TRANS | Liver | Human | 2099 | ESR1 | Gain | 0.09 μM |
| ATG_PXR_TRANS | Liver | Human | 8856 | NR1I2 | Gain | 6.16 μM |
| ATG_RXRb_TRANS | Liver | Human | 6257 | RXRB | Gain | 3.18 μM |
| ATG_Ahr_CIS | Liver | Human | 196 | AHR | Inhibitory | 13.31 μM |
| ATG_AP_1_CIS | Liver | Human | 2353|3725 | FOS|JUN | Inhibitory | 13.09 μM |
| ATG_DR4_LXR_CIS | Liver | Human | 7376|10062 | NR1H2|NR1H3 | Activatory | 12.85 μM |
| ATG_EGR_CIS | Liver | Human | 1958 | EGR1 | Activatory | 11.1 μM |
| ATG_ERE_CIS | Liver | Human | 2099 | ESR1 | Activatory | 0.2 μM |
| ATG_MRE_CIS | Liver | Human | 4520 | MTF1 | Inhibitory | 14.91 μM |
| ATG_NRF2_ARE_CIS | Liver | Human | 4780 | NFE2L2 | Inhibitory | 9.55 μM |
| ATG_PXRE_CIS | Liver | Human | 8856 | NR1I2 | Inhibitory | 5.27 μM |
| ATG_VDRE_CIS | Liver | Human | 7421 | VDR | Activatory | 12.67 μM |
| ATG_ERa_TRANS | Liver | Human | 2099 | ESR1 | Gain | 0.18 μM |
| ATG_PXR_TRANS | Liver | Human | 8856 | NR1I2 | Gain | 5.91 μM |
| ATG_RXRb_TRANS | Liver | Human | 6257 | RXRB | Gain | 5.39 μM |
| ATG_Ahr_CIS | Liver | Human | 196 | AHR | Activatory | 5.94 μM |
| ATG_AP_1_CIS | Liver | Human | 2353|3725 | FOS|JUN | Inhibitory | 6.82 μM |
| ATG_ERE_CIS | Liver | Human | 2099 | ESR1 | Inhibitory | 0.11 μM |
| ATG_HSE_CIS | Liver | Human | 3297 | HSF1 | Inhibitory | 15.46 μM |
| ATG_MRE_CIS | Liver | Human | 4520 | MTF1 | Inhibitory | 13.34 μM |
| ATG_NRF2_ARE_CIS | Liver | Human | 4780 | NFE2L2 | Inhibitory | 7.55 μM |
| ATG_Pax6_CIS | Liver | Human | 5080 | PAX6 | Inhibitory | 8.18 μM |
| ATG_PPRE_CIS | Liver | Human | 5465|5467|5468 | PPARA|PPARD|PPARG | Inhibitory | 5.74 μM |
| ATG_PXRE_CIS | Liver | Human | 8856 | NR1I2 | Inhibitory | 3.74 μM |
| ATG_TCF_b_cat_CIS | Liver | Human | 6932|6934|51176|83439 | TCF7|TCF7L2|LEF1|TCF7L1 | Inhibitory | 8.78 μM |
| ATG_VDRE_CIS | Liver | Human | 7421 | VDR | Inhibitory | 11.1 μM |
| ATG_ERa_TRANS | Liver | Human | 2099 | ESR1 | Gain | 0.13 μM |
| ATG_NURR1_TRANS | Liver | Human | 4929 | NR4A2 | Gain | 11.1 μM |
| ATG_PXR_TRANS | Liver | Human | 8856 | NR1I2 | Gain | 4.89 μM |
| ATG_RXRb_TRANS | Liver | Human | 6257 | RXRB | Gain | 4.24 μM |
| NVS_NR_hER | | Human | 2099 | ESR1 | Loss | 0.11 μM |
| NVS_NR_hGR | | Human | 2908 | NR3C1 | Loss | 0.72 μM |
| NVS_NR_hPPARa | | Human | 5465 | PPARA | Loss | 15.19 μM |
| NVS_NR_mERa | | Mouse | 13982 | Esr1 | Loss | 0.01 μM |
| NVS_NR_rAR | Prostate | Rat | 24208 | Ar | Loss | 4.51 μM |
| NVS_MP_rPBR | Kidney | Rat | 24230 | Tspo | Loss | 7.15 μM |
| NVS_NR_hER | | Human | 2099 | ESR1 | Loss | 0.04 μM |
| NVS_NR_hGR | | Human | 2908 | NR3C1 | Loss | 0.33 μM |
| NVS_NR_rAR | Prostate | Rat | 24208 | Ar | Loss | 1.57 μM |
| NVS_NR_hER | | Human | 2099 | ESR1 | Loss | 0.02 μM |
| NVS_NR_hGR | | Human | 2908 | NR3C1 | Loss | 0.36 μM |
| NVS_NR_mERa | | Mouse | 13982 | Esr1 | Loss | 0.02 μM |
| NVS_NR_rAR | Prostate | Rat | 24208 | Ar | Loss | 2.65 μM |
| ATG_Ahr_CIS | Liver | Human | 196 | AHR | Activatory | 11.1 μM |
| ATG_AP_1_CIS | Liver | Human | 2353|3725 | FOS|JUN | Inhibitory | 11.1 μM |
| ATG_CRE_CIS | Liver | Human | 10488 | CREB3 | Activatory | 11.1 μM |
| ATG_DR4_LXR_CIS | Liver | Human | 7376|10062 | NR1H2|NR1H3 | Inhibitory | 11.1 μM |
| ATG_DR5_RAR_CIS | Liver | Human | 5914|5915|5916 | RARA|RARB|RARG | Inhibitory | 11.1 μM |
| ATG_ERE_CIS | Liver | Human | 2099 | ESR1 | Activatory | 0.13 μM |
| ATG_Ets_CIS | Liver | Human | 2113 | ETS1 | Activatory | 15.47 μM |
| ATG_NRF2_ARE_CIS | Liver | Human | 4780 | NFE2L2 | Inhibitory | 13.92 μM |
| ATG_PPRE_CIS | Liver | Human | 5465|5467|5468 | PPARA|PPARD|PPARG | Activatory | 11.1 μM |
| ATG_PXRE_CIS | Liver | Human | 8856 | NR1I2 | Inhibitory | 4.17 μM |
| ATG_VDRE_CIS | Liver | Human | 7421 | VDR | Activatory | 13.09 μM |
| ATG_ERa_TRANS | Liver | Human | 2099 | ESR1 | Gain | 0.25 μM |
| ATG_PXR_TRANS | Liver | Human | 8856 | NR1I2 | Gain | 5.98 μM |
| ATG_RXRb_TRANS | Liver | Human | 6257 | RXRB | Gain | 4.99 μM |
| BSK_4H_MCP1 | Vascular | Human | 6347 | CCL2 | Inhibitory | 12.45 μM |
| BSK_4H_VEGFRII | Vascular | Human | 3791 | KDR | Inhibitory | 6.04 μM |
| BSK_CASM3C_IL8 | Vascular | Human | 3576 | CXCL8 | Inhibitory | 6.39 μM |
| BSK_hDFCGF_CollagenIII | Skin | Human | 1281 | COL3A1 | Inhibitory | 10.59 μM |
| BSK_hDFCGF_MCSF | Skin | Human | 1435 | CSF1 | Inhibitory | 14.79 μM |
| BSK_hDFCGF_PAI1 | Skin | Human | 5054 | SERPINE1 | Inhibitory | 12.83 μM |
| BSK_hDFCGF_VCAM1 | Skin | Human | 7412 | VCAM1 | Inhibitory | 8.19 μM |
| NVS_ADME_hCYP19A1 | | Human | 1588 | CYP19A1 | Loss | 5.78 μM |
| NVS_ADME_hCYP2B6 | | Human | 1555 | CYP2B6 | Loss | 4.36 μM |
| NVS_ADME_hCYP2C19 | | Human | 1557 | CYP2C19 | Loss | 0.14 μM |
| NVS_ADME_hCYP2C9 | | Human | 1559 | CYP2C9 | Loss | 0.4 μM |
| NVS_ADME_hCYP3A4 | | Human | 1576 | CYP3A4 | Loss | 7.6 μM |
| NVS_ADME_hCYP4F12 | | Human | 66002 | CYP4F12 | Loss | 3.03 μM |
| NVS_ENZ_hAMPKa1 | | Human | 5562 | PRKAA1 | Loss | 13.51 μM |
| NVS_ENZ_hMMP1 | | Human | 4312 | MMP1 | Loss | 3.66 μM |
| NVS_GPCR_g5HT4 | Brain | Guinea pig | 100135548 | Htr4 | Loss | 11.68 μM |
| NVS_GPCR_gLTB4 | Spleen | Guinea pig | 100379538 | Ltb4r | Loss | 0.44 μM |
| NVS_GPCR_gOpiateK | Brain | Guinea pig | 100135587 | Oprk1 | Loss | 14.05 μM |
| NVS_GPCR_h5HT2A | Brain | Human | 3356 | HTR2A | Loss | 7.43 μM |
| NVS_GPCR_h5HT6 | | Human | 3362 | HTR6 | Loss | 0.35 μM |
| NVS_GPCR_hAdra2C | | Human | 152 | ADRA2C | Loss | 9.87 μM |
| NVS_GPCR_hAdrb1 | | Human | 153 | ADRB1 | Loss | 15.03 μM |
| NVS_GPCR_hDRD1 | | Human | 1812 | DRD1 | Loss | 2.7 μM |
| NVS_GPCR_hOpiate_mu | | Human | 4988 | OPRM1 | Loss | 3.6 μM |
| NVS_IC_rNaCh_site2 | Brain | Rat | 81574 | Scn1a | Loss | 5.87 μM |
| NVS_LGIC_rGluNMDA_Agonist | Brain | Rat | 24408 | Grin1 | Gain | 15.09 μM |
| NVS_NR_hAR | | Human | 367 | AR | Loss | 3.09 μM |
| NVS_NR_hGR | | Human | 2908 | NR3C1 | Loss | 0.71 μM |
| NVS_NR_hPR | | Human | 5241 | PGR | Loss | 1.32 μM |
| NVS_NR_mERa | | Mouse | 13982 | Esr1 | Loss | 0.07 μM |
| NVS_NR_rAR | Prostate | Rat | 24208 | Ar | Loss | 4.93 μM |
| NVS_NR_rMR | Brain | Rat | 25672 | Nr3c2 | Loss | 13.95 μM |
| NVS_TR_gDAT | Brain | Guinea pig | 100714898 | Slc6a3 | Loss | 11.59 μM |
| NVS_TR_hNET | | Human | 6530 | SLC6A2 | Loss | 13.57 μM |
| NVS_GPCR_gMPeripheral_NonSelective | Bladder | Guinea pig | 100379235 | Chrm3 | Loss | 13.58 μM |
| NVS_GPCR_h5HT5A | | Human | 3361 | HTR5A | Loss | 10.39 μM |
| NVS_GPCR_h5HT7 | | Human | 3363 | HTR7 | Loss | 5.71 μM |
| NVS_GPCR_hDRD2s | | Human | 1813 | DRD2 | Loss | 7.58 μM |
| NVS_GPCR_hDRD4.4 | | Human | 1815 | DRD4 | Loss | 14.07 μM |
| NVS_GPCR_hOpiate_D1 | | Human | 4985 | OPRD1 | Loss | 10.5 μM |
| NVS_NR_hCAR_Antagonist | | Human | 9970 | NR1I3 | Loss | 0.0 μM |
| NVS_NR_hER | | Human | 2099 | ESR1 | Loss | 0.15 μM |
| NVS_TR_rVMAT2 | Brain | Rat | 25549 | Slc18a2 | Loss | 10.11 μM |
| ATG_hERa_XSP1 | Liver | Human | 2099 | ESR1 | Gain | 0.04 μM |
| ATG_hERb_XSP1 | Liver | Human | 2100 | ESR2 | Gain | 0.01 μM |
| ATG_hERa_XSP1 | Liver | Human | 2099 | ESR1 | Gain | 0.13 μM |
| ATG_hERb_XSP1 | Liver | Human | 2100 | ESR2 | Gain | 0.08 μM |
| ATG_hERa_XSP2 | Liver | Human | 2099 | ESR1 | Gain | 0.41 μM |
| ATG_hERb_XSP2 | Liver | Human | 2100 | ESR2 | Gain | 0.06 μM |
| TOX21_ERa_BLA_Agonist_ratio | Kidney | Human | 2099 | ESR1 | Gain | 0.45 μM |
| TOX21_ERa_LUC_VM7_Agonist | Breast | Human | 2099 | ESR1 | Gain | 0.06 μM |
| TOX21_GR_BLA_Antagonist_ratio | Cervix | Human | 2908 | NR3C1 | Loss | 10.38 μM |
| TOX21_TR_LUC_GH3_Antagonist | Pituitary gland | Rat | 7067|7068 | THRA|THRB | Loss | 13.2 μM |
| TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881 | Breast | Human | 367 | AR | Loss | 14.69 μM |
| TOX21_CAR_LUC_Agonist | Liver | Human | 9970 | NR1I3 | Gain | 10.63 μM |
| TOX21_CAR_LUC_Antagonist | Liver | Human | 9970 | NR1I3 | Loss | 0.72 μM |
| TOX21_ERb_BLA_Antagonist_ratio | Kidney | Human | 2100 | ESR2 | Loss | 0.37 μM |
| TOX21_PR_BLA_Antagonist_ratio | Kidney | Human | 5241 | PGR | Loss | 10.74 μM |
| TOX21_ERa_LUC_VM7_Agonist_10nM_ICI182780 | Breast | Human | 2099 | ESR1 | Gain | 3.12 μM |
| TOX21_p450_CYP2C19_Antagonist | | Human | 1557 | CYP2C19 | Loss | 4.18 μM |
| TOX21_p450_CYP2C9_Antagonist | | Human | 1559 | CYP2C9 | Loss | 2.71 μM |
| TOX21_ERa_BLA_Agonist_ratio | Kidney | Human | 2099 | ESR1 | Gain | 1.07 μM |
| TOX21_ERa_LUC_VM7_Agonist | Breast | Human | 2099 | ESR1 | Gain | 0.19 μM |
| TOX21_GR_BLA_Antagonist_ratio | Cervix | Human | 2908 | NR3C1 | Loss | 11.43 μM |
| TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881 | Breast | Human | 367 | AR | Loss | 12.61 μM |
| TOX21_AP1_BLA_Agonist_ratio | Cervix | Human | 2353|3725 | FOS|JUN | Gain | 14.37 μM |
| TOX21_CAR_LUC_Agonist | Liver | Human | 9970 | NR1I3 | Gain | 6.88 μM |
| TOX21_CAR_LUC_Antagonist | Liver | Human | 9970 | NR1I3 | Loss | 1.38 μM |
| TOX21_ERb_BLA_Antagonist_ratio | Kidney | Human | 2100 | ESR2 | Loss | 0.33 μM |
| TOX21_PR_BLA_Antagonist_ratio | Kidney | Human | 5241 | PGR | Loss | 11.14 μM |
| TOX21_ERa_LUC_VM7_Agonist_10nM_ICI182780 | Breast | Human | 2099 | ESR1 | Gain | 5.66 μM |
| TOX21_p450_CYP2C19_Antagonist | | Human | 1557 | CYP2C19 | Loss | 4.84 μM |
| TOX21_p450_CYP2C9_Antagonist | | Human | 1559 | CYP2C9 | Loss | 2.72 μM |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.